Alerta

CRYPTOCOCCAL NANO-IMMUNOTHERAPY: A FUNGAL DRUG CARRIER PLATFORM

Resumen de: WO2026006769A1

The present invention provides a fungal drug carrier comprising an avirulent fungal pathogen cell, for example a Cryptococcus neoformans cell, linked to one or more surface-bound drug-loaded nanoparticles, and methods of making the fungal drug carrier. The invention provides methods of using the fungal drug carrier to deliver a drug to the central nervous system of a patient, wherein the fungal drug carrier is phagocytosed by an immune cell of a patient, transported across the blood-brain barrier, and vomocytosed to allow drug release from the surface-bound nanoparticle into the central nervous system of the patient. The methods involve treating a central nervous system in a patient comprising administering to the patient a pharmaceutical composition comprising a fungal drug carrier.

A SYSTEM FOR DELIVERING GENETIC MATERIAL SUBCUTANEOUSLY WITH ELEMENTS ENABLING SUBSEQUENT POST-TREATMENT IDENTIFICATION, LOCALIZATION, QUANTIFICATION, EVALUATION, OR TARGETING FOR UP- AND/OR DOWN-TITRATION

Resumen de: WO2026006281A1

Provided herein is a system for delivering genetical material, preferably subcutaneously, and its various elements. Also provided are related compositions and methods.

ENZYME ENCAPSULATED NANOPARTICLES

Resumen de: WO2026006092A1

Provided herein are compositions, systems, kits, and methods for treating a patient with a disease or condition by administering nanoparticles comprising a biocompatible polymer, wherein the nanoparticles fully, or almost fully, encapsulate: i) tissue-type plasminogen activator (tPA), ii) at least one antioxidant enzyme selected from: superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase, and optionally iii) plasmin protein. In certain embodiments, the disease or condition is selected from: thromboembolism, ischemia-reperfusion injury, stroke, spinal cord injury (SCI), Alzheimer's disease, Muscular Dystrophy, Hypercoagulability, Vaso-occlusive conditions, a fibrotic condition, internal tissue scarring, peritoneal scarring, wound associated scarring, surgical incision associated scarring, and/or dermal scarring.

USE OF BLOCK COPOLYMERS COMPRISING A POLY(ETHYLENE OXIDE) WITH A C1 TO C3-ALKYLOXYMETHYL SIDE CHAINS BLOCK AND HYDROPHOBIC BLOCKS IN PARTICLES AND IN MEDICAL DEVICES

Resumen de: WO2026002534A1

The present invention refers to the use of novel polyoxyalkylene based block copolymers in particles or in medical devices, wherein the particles comprise at least one novel polyoxyalkylene based block copolymer and preferably at least one active agent.

TRANSITION METAL DICHALCOGENIDE (TMD)-BASED ANTIBODY MIMETIC, IMMUNOTHERAPEUTIC AGENT COMPRISING SAME, AND PREPARATION METHOD THEREFOR

Resumen de: WO2026005574A1

Provided are transition metal dichalcogenide (TMD)-based antibody mimetic comprising: a transition metal dichalcogenide nanosheet; and a tripeptide bound to the nanosheet. The antibody mimetic according to the present invention can strongly bind to PD-L1 with a dissociation constant at the nanomolar level, and can selectively bind to albumin and immunoglobulin (IgG1), which are major plasma proteins, at least 1.5 times more selectively. As a result, imaging of PD-L1-overexpressing cancer cells is possible by treating PD-L1-overexpressing cancer cells with a TMD nanosheet antibody mimic so as to detect the Raman scattering signal, which is an intrinsic optical characteristic of the material. In addition, the PD-L1/PD-1 binding blocking effect of the TMD nanosheet antibody mimetic, according to the present invention, can be identified at the cell level and the cancer cell transplantation animal model level, and thus the TMD nanosheet antibody mimetic can also function as an immunotherapeutic agent.

AUTOANTIGEN-SPECIFIC NANOFUSION VACCINE COMPOSITION FOR TREATMENT OF SYSTEMIC SCLEROSIS FOR SIMULTANEOUS IMMUNOMODULATION AND ANTIFIBROSIS

Resumen de: WO2026005488A1

The present invention relates to an autoantigen-specific nanofusion vaccine composition for the treatment of systemic sclerosis, the composition being for simultaneous immunomodulation and antifibrosis. A nanofusion body carrying a vimentin peptide according to the present invention was found to inhibit tissue fibrosis in systemic sclerosis, reduce the amount of autoantibodies in serum, and regulate the expression of immune-regulatory cells and pathogenic cells associated with systemic sclerosis. The nanofusion body was also found to inhibit tissue fibrosis and to exhibit enhanced anti-fibrotic effects, when co-administered with a vimentin antibody, in an animal model reflecting the immune status of systemic sclerosis patients. In addition, the nano-vaccine was found to decrease the expression of fibrotic and pathogenic factors in tissues and was also found to improve disease activity not only in vimentin-specific systemic sclerosis but also in infection-associated systemic sclerosis.

ALTERED MODIFIED BORON CARBIDE PARTICLES AND NEUTRON CAPTURE THERAPY AGENT COMPRISING SAME

Resumen de: WO2026005041A1

The present invention provides a neutron capture therapy agent with a superior therapeutic effect.　The present invention provides modified boron carbide nanoparticle powder with a suitable particle diameter for polyglycerol-functionalized boron carbide, capable of producing a boron neutron capture therapy (BNCT) agent that exhibits high accumulation efficiency in tumors and excellent therapeutic efficacy, with the surface of the boron carbide nanoparticles not coated with graphite.

METHOD FOR PRODUCING LIPID NANOPARTICLES

Resumen de: WO2026004828A1

The present invention addresses the problem of providing a method for producing lipid nanoparticles, the method making it possible to produce lipid nanoparticles having a narrow particle size distribution. The present invention provides a method for producing lipid nanoparticles, the method comprising a step 1 for preparing a first solution containing an active ingredient, a step 2 for preparing a second solution containing a prescribed lipid and an alcohol, a step 3 for mixing the first solution and the second solution in a flow channel to prepare a lipid nanoparticle dispersion, a step 4 for mixing and diluting the lipid nanoparticle dispersion A with a third solution at a given ratio and thereby preparing a lipid nanoparticle dispersion B, and a step 5 including a pH adjustment step for adjusting the pH of the lipid nanoparticle dispersion B and an alcohol removal step, the interval from step 3 to step 4 being less than 1 minute, and the alcohol content of the lipid nanoparticle dispersion B being 6-30 vol%.

METHOD FOR PRODUCING LIPID NANOPARTICLES

Resumen de: WO2026004829A1

The present invention addresses the problem of providing a method for producing lipid nanoparticles, which enables the production of lipid nanoparticles having a narrow particle size distribution. According to the present invention, there is provided a method for producing lipid nanoparticles, the method comprising a step 1 for preparing a first solution that is an acidic aqueous solution containing an active ingredient, a step 2 for preparing a second solution that is a solution containing a specific lipid and an alcohol; a step 3 for preparing a lipid nanoparticle dispersion by mixing the first solution with the second solution in a flow channel, a pH adjustment step for adjusting the pH of the lipid nanoparticle dispersion, and an alcohol removal step, wherein the alcohol content in the lipid nanoparticle dispersion obtained in step 3 is 12.5-33 vol%, and the lipid nanoparticle dispersion is held for 1 minute or more after the completion of the step 3.

MRNA BASED CFTR PRECURSOR AND PREPARATION METHOD THEREOF

Resumen de: WO2026003875A1

The present disclosure discloses a messenger ribonucleic acid (mRNA) molecule encoding for a cystic fibrosis transmembrane conductance regulator (CFTR) protein. The mRNA molecule is encoded by SEQ ID No. 25 or a sequence having 95% identity to SEQ ID No. 25.

MULTISUBUNIT HERPESVIRUS VACCINES AND THERAPEUTICS

Resumen de: WO2026003586A2

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a herpesvirus. The multisubunit nucleic acid encodes a multisubunit peptide.

MULTISUBUNIT HEPACIVIRUS VACCINES AND THERAPEUTICS

Resumen de: WO2026003577A1

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a hepacivirus. The multisubunit nucleic acid encodes a multisubunit peptide.

MULTISUBUNIT RSV, HMPV AND HPIV VACCINES AND THERAPEUTICS

Resumen de: WO2026003578A1

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a respiratory syncytial virus, a metapneumovirus, a human parainfluenza virus, or a combination thereof. The multisubunit nucleic acid encodes a multisubunit peptide.

MULTISUBUNIT PAPILLOMAVIRUS VACCINES AND THERAPEUTICS

Resumen de: WO2026003579A1

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of self-assembling immunogenic sequences or a plurality of self-assembling immunogenic sequences each further comprising one or more target sequence, or a combination thereof, wherein each self-assembling immunogenic sequence of the plurality is connected to an adjacent self-assembling immunogenic sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises one or more signal sequence upstream of one or more of the self-assembling immunogenic sequences of the plurality. Also disclosed are multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein some or all polynucleotide sequences of the plurality comprises a plurality of self-assembling immunogenic sequence, or a plurality of self-assembling immunogenic sequence each further comprising one or more target sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by one or more cleavage sequence and wherein the multisubunit nucleic acid further comprises one or more signal sequence upstream of one or more of the polynucleotide sequence of the plurality. The multisubunit nucleic acid encodes multisubunit peptide.

NITROGEN-CONTAINING CHAIN COMPOUND, PREPARATION METHOD, COMPOSITION INCLUDING SAME, AND APPLICATION

Resumen de: WO2026002273A1

Disclosed are a nitrogen-containing chain compound, a preparation method, a composition including same, and an application. Specifically, provided are a nitrogen-containing chain compound as shown in formula (I), or a pharmaceutically acceptable salt thereof. An LNP preparation prepared by using the nitrogen-containing chain compound has a relatively uniform nanoparticle size, a high encapsulation efficiency, and high in vivo expression activity.

NANO-FORMULATION FOR CLEARING SENESCENT CELLS, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2026000480A1

A nano-formulation for clearing senescent cells, a preparation method therefor, and use thereof. A gingerenone A-loaded aminated dendritic mesoporous silica nano-formulation is constructed. Dendritic mesoporous silica having a unique central radial pore structure is selected as a drug carrier; the drug carrier is further modified with amino groups, and gingerenone A is loaded onto the aminated dendritic mesoporous silica via non-covalent interactions. The obtained nano-formulation has a uniform particle size, and exhibits the characteristics of high drug loading, high encapsulation efficiency, high biocompatibility, rapid cellular uptake, and low cytotoxicity. Moreover, the nano-formulation can significantly enhance the ability of gingerenone A to clear senescent cells, thereby improving the bioavailability of gingerenone A, and broadening the clinical application of gingerenone A. The nano-formulation has good application prospects in functional foods, pharmaceuticals, and cosmetics.

SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS

Resumen de: WO2026000081A1

Embodiments disclosed herein relate to sulfur-containing lipids. Examples of lipids described herein have a structure of Formula (A) or a pharmaceutically acceptable salt thereof. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.

IONIZABLE LIPIDS COMPRISING CYCLIC MOIETIES FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS

Resumen de: WO2026000083A1

Provided herein are novel sulfur-containing lipids having a structure of Formula (A) or a salt thereof. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.

IONIZABLE LIPIDS WITH MODIFIED HEAD GROUPS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS

Resumen de: WO2026000082A1

Embodiments described herein are directed to lipids having a structure of Formula (A) or a salt thereof and wherein A is carbon or nitrogen and the head group comprises a moiety of Formula (B). A1 and A2 are, independently, O or S and G1, G2 and G3 are as defined herein. The lipids may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.

一种包载异鼠李素的肉苁蓉来源外泌体及制备方法和应用

Resumen de: CN121243112A

本发明属于生物制药技术领域，具体涉及一种包载异鼠李素的肉苁蓉来源外泌体及制备方法和应用。本发明提供了一种负载异鼠李素的肉苁蓉外泌体（ISO@CD），以强化对氧化应激与线粒体功能的调控，协同增强DMED治疗效果。

一种“靶-药”自适转变交联自组装纳米平台及其制备方法和应用

Resumen de: CN121243110A

本发明属于药物递送系统构建领域，具体涉及一种“靶‑药”自适转变交联自组装纳米平台及其制备方法和应用。本发明创造性的将阿霉素作为自身口服递送的载体和靶向配体，实现了肿瘤部位的特异性靶向和治疗作用。通过特定的交联材料以二硫键交联将盐酸阿霉素稳定自组装，并使其亲水端糖环锚定在纳米粒表面，通过识别肠上皮细胞顶侧膜上高表达的SGLT1、OCTN2和基底侧的GLUT2，脑微血管内皮细胞和胶质瘤细胞表面的GLUT1从而跨越肠上皮细胞屏障和血脑屏障。该纳米粒不仅显著提高了阿霉素的口服生物利用度，且在脑部有高效的蓄积作用，进一步在高GSH环境下，断裂二硫键，释放阿霉素，实现了安全高效的抗肿瘤作用。

一种基于基因工程化细菌外膜囊泡-脂质体融合的超声响应性纳米颗粒及其制备方法和应用

Resumen de: CN121243375A

本发明属于生物医药技术领域，具体公开了一种基于基因工程化细菌外膜囊泡‑脂质体融合的超声响应性纳米颗粒及其制备方法和应用。本发明提供的纳米颗粒OL@Ce6可通过三重协同机制突破肿瘤免疫治疗瓶颈：(1)免疫靶向强化：融合外壳中OMVs富含的PAMPs可被肿瘤微环境中抗原呈递细胞高效识别，显著提升肿瘤抗原递呈效率；(2)智能免疫调控：内核缓释的GM‑CSF强力募集DCs至肿瘤微环境并促进其成熟，建立持续性免疫应答枢纽；(3)声动力‑免疫协同：脂质双分子层中嵌入的声敏剂在超声辐照下爆发ROS，精准诱导肿瘤细胞ICD并释放DAMPs，激活细胞毒性T淋巴细胞深度浸润，形成抗肿瘤免疫正反馈循环。

一种钴酸钙压电声敏剂的制备方法及其应用

Resumen de: CN121243380A

本发明公开一种钴酸钙压电声敏剂的制备方法及其在肿瘤治疗中的应用。以硝酸钙、硝酸钴为原料，溶于柠檬酸水溶液并加2%PEG形成前驱液，经80℃水解缩合得溶胶、陈化得凝胶，120℃干燥12小时后800℃煅烧2小时制钴酸钙纳米颗粒，再经PVP表面修饰得钴酸钙压电声敏剂。该声敏剂生物相容性与稳定性良好，具优异压电响应，超声下可形成内置电场，促进电子‑空穴对的分离并抑制其快速复合，提高活性氧产率，可用于肿瘤声动力治疗。其制备装置简易、操作简单、周期快，利于量产，为肿瘤声动力治疗提供新型高效纳米材料平台。

一种普鲁士蓝肉桂醛纳米酶复合物及其制备方法和应用

Resumen de: CN121243410A

本发明公开了一种普鲁士蓝肉桂醛纳米酶复合物及其制备方法和应用，属于生物医药技术领域。该复合物由普鲁士蓝纳米颗粒通过共价键或物理吸附负载肉桂醛构成，具有pH响应释放特性、良好的稳定性及协同抗炎抗氧化活性。其制备方法简单、条件温和、易于规模化。实验表明，该复合物能显著改善溃疡性结肠炎小鼠的疾病症状，降低炎症因子水平，增强抗氧化能力，效果优于单一成分，具有良好的临床应用前景。

一种荧光示踪的靶向光热抗肿瘤纳米颗粒的制备方法

Nº publicación: CN121243374A 02/01/2026

Solicitante:

中国人民解放军空军军医大学

Resumen de: CN121243374A

本发明公开了一种荧光示踪的靶向光热抗肿瘤纳米颗粒的制备方法，包括如下步骤：步骤1、制备含铁钛酸钡纳米颗粒BaTiO3/Fe；步骤2、用聚乙烯亚胺包裹BaTiO3/Fe，得到含铁钛酸钡纳米颗粒BaTiO3/Fe‑PEI；步骤3、将叶酸、N‑羟基琥珀酰亚胺和二氯乙烷溶解于超纯水中，磁力搅拌，使用NaOH溶液调节pH值至10，得到混合溶液A，将BaTiO3/Fe‑PEI分散于混合溶液A，搅拌反应24h，得到反应液B，透析，离心分离出固体产物，洗涤，得到肿瘤靶向纳米颗粒BaTiO3/Fe‑PEI‑FA；步骤4、将BaTiO3/Fe‑PEI‑FA分散于含有吲哚菁绿的磷酸盐缓冲液，避光反应12h，离心分离出固体产物，洗涤，冷冻干燥，得到荧光示踪的靶向光热抗肿瘤纳米颗粒BaTiO3/Fe‑PEI‑FA/ICG，具有良好的肿瘤靶向性和成像可视性，能够在超声和磁共振双模式成像引导下协同治疗肿瘤。